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This article presents a clinical approach to patchy, non-scarring hair loss and includes conditions like alopecia areata, trichotil-
lomania, dermatophyte infection of the scalp, syphilitic alopecia and traction folliculitis.
 Scarring hair loss
 Primary
 Lymphocyte associated
  •  Lichen planus
  •  Lupus erythematosus
  •  Pseudopelade of Brocq
  •  Follicular mucinosis
  Neutrophil associated
  •  Folliculitis decalvans
  •  Diffecting folliculitis
  •  Folliculitis keloidalis nuchae
  Secondary
  •  Trauma
  •  Radiotherapy
  •  Some dermatophyte infections
  •  Primary neoplasia
  •  Secondary neoplasia (metastasis)
 Non-scarring hair loss
  On an abnormal scalp
  •  Psoriasis
  •  Seborrhoeic dermatitis
  •  Some dermatophyte infections
  •  Traction alopecia
 On a normal scalp
  Diffuse
  •  Telogen hair loss
  •  Anagen hair loss
  Patchy
  •  Alopecia areata
  •  Triangular alopecia
  •  Trichotillomania  
 •  Secondary syphilis  
 With a distinct pattern  
 •  Male pattern baldness  
 •  Female pattern baldness
 Other causes of hair loss
  •  Hair shaft abnormalities
  •  Congenital hypotrichosis
  •  Loose anagen syndrome
Table I: Causes of hair loss
Introduction
Shedding of hair is termed effluvium or 
defluvium, and the resulting condition is 
called alopecia (Greek: alópekia, [bald-
ness]). The normal scalp is adorned with 
approximately 100 000 hairs. More than 
90% are in the growing phase (anagen). 
Up to 100 hairs may normally be shed 
per day. Individuals are often aware of 
and very concerned about subtle thin-
ning of their hair. Patients presenting 
with hair loss are commonly encoun-
tered in clinical practice. The causes of 
hair loss are outlined in Table I.  
Differences between scarring and non-
scarring hair loss are summarised in 
Table II.
Five conditions frequently encoun-
tered in clinics and presenting with 
patchy, non-scarring hair loss, are alo-
pecia areata, trichotillomania, dermato-
phyte infection of the scalp, secondary 
syphilis, and traction folliculitis/alopecia.
Alopecia areata
Alopecia areata (AA) is an autoimmune 
disease caused by interaction of T-lym-
phocytes and follicular epithelium result-
ing in progressive shrinkage of follicles 
and loss of hair. In case of fulminant AA, 
Non-scarring hair loss Scarring hair loss




Loss of follicular 
openings - +
Tufted hair* - +
Course regrowth is quite common no regrowth
Prognosis generally favourable generally unfavourable
*  Tufted hair - more than one hair shaft emerge from a single follicular opening as a result of 
abnormal follicular dynamics related to fibrosis.
Figure 1:  Alopecia areata. The scalp ap-
pears normal. (Figure courtesy of 
Derm101.com)
persons may experience “going grey 
overnight”. Alopecia occurs in round or 
oval areas without any visible inflamma-
tion of the skin (Figure 1). 
There may be one, or several, discrete 
or confluent patches. Follicular open-
ings are present. No atrophy or scar-
ring occurs. The most common present-
ing area is the scalp, but the eyebrows, 
eyelashes, pubic hair and beard may 
also be involved. Alopecia areata tota-
lis (AAT) refers to total absence of ter-
minal scalp hair (Figure 2) and alope-
cia areata universalis (AAU) to total loss 
of terminal body and scalp hair. Ophia-
sis is characterised by a bandlike pat-
Figure 2:  Alopecia totalis. Eyebrow hair is 
also sparse. (Figure courtesy of 
Derm101.com)
Table II:  Non-scarring hair loss versus scarring hair loss
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tern of hair loss over the periphery of the 
scalp. Hair loss usually develops grad-
ually over weeks to months. Patches of 
AA can be stable and often show spon-
taneous regrowth over a period of sev-
eral months; new patches may appear 
while others resolve. AA is asymptomat-
ic but individuals are usually very con-
cerned about the hair loss and possible 
continued, progressive balding.
Occasionally diagnostic, broken-off, 
stubbly hairs called exclamation point 
hairs (distal ends are broader than 
proximal ends) are present. With the 
regrowth of hair, new hairs are fine, of-
ten white or grey. Microscopy of the skin 
shows peribulbar lymphocytes, likened 
to a “swarm of bees”, and miniaturisa-
tion of hair follicles.
The nails may show fine pitting (“ham-
mered brass”) of the dorsal nail plate, 
mottled lunulae, trachyonychia (rough 
nails) and onychomadesis (separation 
of nail from matrix). Associated findings 
include Hashimoto’s thyroiditis, vitiligo, 
myasthenia gravis and Addison’s dis-
ease. 
Differential diagnosis
In the differential diagnosis, second-
ary syphilis, grey-patch tinea capitis, 
trichotillomania, traction alopecia, early 
chronic cutaneous lupus erythematosus 
and androgenetic alopecia should be 
considered. The differences between 
trichotillomania and alopecia areata are 
outlined in Table III.
Course
Spontaneous remission is common in 
patchy AA. Poor prognosis is associ-
ated with a number of factors (Table 
IV). If AA occurs after puberty, 80% of 
patients experience hair regrowth within 
a year. Recurrences of AA are, however, 
frequent.
Table III:   Differential diagnosis of trichotillotic hair loss and alopecia areata





Peak:  second and fifth 
decades
Compulsive psychosomatic disorder
Females:males   =    2:3 in children
Females:males   =    4:1 in adults
Children:adults   =    7:1 peak two 
                                  to six years
History Sudden onset, no history of hair pulling




Circumscribed, smooth, totally 
bald patch; residual exclama-
tion hairs; loose marginal hairs 
(in the active stage)
Ill-defined, uneven alopecia with 
broken hairs of different lengths:  ex-
clamation hairs and strong marginal 
hairs may be present
Histopathology
Increased telogen hairs, lym-
phocytic infiltrate around ana-
gen follicles; miniaturised folli-
cles; amelanotic hairs
Increased catagen hairs; no inflam-
matory infiltrate; traumatised hair 
bulbs with haemorrhage; trichoma-
lacia (specific)
Nails Nail pitting (dystrophic plate changes)




Psychological abnormality found 
in 90%, with a triggering emotion-
al stress common
Obsessive-compulsive disorder
Associations Atopic and autoimmune diseases Atopic diseases, anaemia
Prognosis
Good, except in certain groups 
(atopic, early onset, ophiatic and 
extensive forms)
Fair in children, poor in adults
Relapse rate 100% Recurrent in adults
Treatment Reassurance, steroids, topical immunotherapy
Reassurance, antidepressants, psy-
chotherapy
Table IV:  Factors indicative of poor prognosis
• Ophiasis (bandlike pattern)
• Alopecia areata totalis
• Alopecia areata universalis
• Onset < five years of age
• Duration > five years of age
• Atopy
Management
No cure is currently available. Remis-
sion may be induced but the course is 
not altered. Treatment for AA is gener-
ally unsatisfactory. In many cases, the 
most important factor in the manage-
ment of the patient is psychological sup-
port from the dermatologist, family, and 
support groups. Individuals may prefer 
to wear a wig. Make-up applied to the 
eyebrows is helpful.
The first line of treatment is the appli-
cation of a potent steroid cream twice 
daily for six weeks. If there is no im-
provement, this treatment should be 
terminated. Few and small spots of AA 
can be treated with an intralesional ste-
roid. Tufted regrowth of hair common-
ly results.
Systemic glucocorticoids usually in-
duce regrowth, but AA recurs on discon-
tinuation. The risks of long-term therapy 
therefore rule out their use. Systemic cy-
closporin induces regrowth, but AA re-
curs when the drug is discontinued. Cy-
closporin is costly and renal damage is 
troublesome. Induction of allergic con-
tact dermatitis with nitrochlorobenzene, 
squaric acid dibutylester, or diphency-
prone can be used successfully, but lo-
cal discomfort due to allergic contact 
dermatitis, and the swelling of region-
al lymph nodes, poses a problem. Oral 
PUVA (photochemotherapy) is variably 
effective, as high as 30%, and worth a 
trial in patients who are very distressed 
by the problem. The entire body must be 
exposed since the therapy is believed to 
be a form of systemic immune suppres-
sion. PUVA treatment has many side ef-
fects, the most important being nausea, 
photosensitivity and the development of 
nonmelanoma skin cancer.
Trichotillomania
Trichotillomania (TTM), first described 
by Halopeau in 1889, is an obsessive-
compulsive disorder, characterised 
by the irresistible urge to pull out hair. 
There is a sensation of relief after the 
pulling episodes. The psychological 
stimulus is satisfied by hair plucking, 
but the resulting unsightly alopecia fuels 
the anxiety of the patient and results in a 
vicious cycle.
Adult TTM is more frequently chronic 
and is associated with more profound 
psychopathy. Adult TTM is more com-
mon in females (females:males 15:1). 
Childhood TTM is more common and 
also more common in females (females:
males 4:1). TTM usually involves the 
Figure 3:  Trichotillomania. Hairs are thin 
and of different lengths. (Figure 
courtesy of Derm101.com)
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scalp, but sometimes the eyebrows or 
eyelashes are plucked. Manual domi-
nance is characteristic: left-sided lesions 
develop in right-handed patients and 
vice versa. Lesions are ill-defined and 
the scalp surface is normal (Figure 3).  
The stubble of unevenly broken hairs is 
highly characteristic. The residual stub-
ble hair has a normal colour and tex-
ture. Sometimes dystrophic “exclama-
tion hairs” may also be found in TTM. 
The differences between AA and TTM 
are outlined in Table III.
Dermatophyte infection of the scalp
Tinea capitis is most commonly caused 
by Trichophyton violaceum of the spe-
cies trichophyton. The infection is usu-
ally spread from person to person. 
Infection by species of the genus mi-
crosporum is less common. Microspo-
rum infection is usually acquired from 
cats or dogs.
The clinical presentation of this dermato-
phyte infection is variable, the common-
est being grey-patch tinea capitis. The 
number of lesions is variable. A single 
lesion may be present, but more com-
monly one finds several lesions. Lesions 
show loss of hair and greyish, tightly 
packed, small scales (Figure 4).  
diculosis should always be borne in 
mind.
The diagnosis of tinea capitis can of-
ten be established clinically, and can be 
confirmed by microscopy of skin scrap-
ings or hair plucked from involved ar-
eas. Such samples can also be des-
patched for culture on Sabouraud’s 
dextrose agar. A therapeutic trial of anti-
fungal treatment remains an acceptable 
alternative.
The treatment of choice is griseoful-
vin  10 - 20 mg/kg per day, with a meal, 
for 6 to 8 weeks.  Patients should be fol-
lowed up to ensure adequate healing of 
the infection. Regular use of a shampoo 
containing povidone-iodine decreases 
the shedding of spores.
Syphilitic alopecia (Secondary 
syphilis)
Secondary syphilis, the stage of spiro-
chaetemia, is characterised by constitu-
tional symptoms, variable organ involve-
ment, generalised lymphadeno-pathy, 
skin eruptions, mucosal lesions, muco-
cutaneous lesions and hair loss. Skin 
eruptions include macular, papular, 
papulosquamous, nodular and pustular 
variants. The skin rash is usually asymp-
tomatic and symmetrical. The palms 
and soles are commonly involved. In 
late stage secondary syphilis, lesions 
often show an arciform, annular or cory-
Figure 4:  Dermatophyte infection of the 
scalp. Multiple areas of hair loss 
with scaling.
Yellow-patch tinea capitis is a relat-
ed condition. Lesions are covered with 
yellowish crusts caused by secondary 
pyoderma. Tinea capitis may also be 
seborrhoeic dermatitis-like and pustu-
lar. Black-dot tinea capitis is charac-
terised by patches of alopecia studded 
with black dots which represent broken-
off hair shafts packed with spores. Ab-
scess-like lesions, e.g. kerion, and le-
sions displaying saucer-shaped scales 
(= scutulae) e.g. favus, are infrequent. 
Secondary pyoderma and cervical 
lymphadenopathy are often present. 
Pyoderma may lead to scarring (Figure 
5). When pyoderma of the scalp is ob-
served, tinea capitis, scabies and pe-
Figure 5:  Dermatophyte infection of the 
scalp. Multiple areas of hair loss 
with scarring.
imbiform pattern. Snail track ulcers are 
commonly observed on the oral muco-
sa and flat, glistening condylomata lata 
are present at moist mucocutaneous 
junctions. Syphilitic alopecia is charac-
terised by patches of hair loss on the 
scalp. These patches show normal skin. 
The pattern is typically described as 
moth-eaten (Figure 6). No particular pat-
tern is observed. A clinical diagnosis of 
secondary syphilis is confirmed by ap-
propriate serological tests. A skin biop-
sy may be helpful. Treatment with peni-
cillin is usually curative.
Traction folliculitis/alopecia
Hair and scalp diseases induced by 
traumatic hairstyling techniques, such 
as tightly drawn braids (Figure 7), are 
underappreciated.  
Figure 6:  Syphilitic alopecia. The scalp has 
a moth-eaten appearance, eye-
brow hair is absent and there is a 
rash on the cheek.
Figure 7:  Traction alopecia. Traction follicu-
litis is commonly associated.
A geometric pattern with the hair sec-
tioned into squares or bands is highly 
characteristic. The hair in each square 
or band is pulled tightly to the centre 
and then secured with a hair band. 
Maximum traction is produced round 
the outer edges of the square or band 
with less traction in the centre. The first 
noticeable changes are faint erythema, 
some scaling and follicular mini pustules. 
Subsequently, in the areas of maximum 
traction, follicle-based papules and pus-
tules associated with alopecia become 
evident. Hair loss and follicle-based 
papules and pustules along the frontal 
scalp margin are common. The pustules 
are sterile. This form of hair loss is also 
common in persons wearing a ponytail 
or bangs. Other hairstyles that can 
lead to traction folliculitis include hair 
twists worn by Sikh boys, chignons, hair 
weaving and hair extensions. Traction 
folliculitis may be associated with hair 
casts. These casts encircle the hair 
shaft, are yellowish white and are freely 
mobile. The units of pediculosis capi-
tis are firmly fastened and immobile. 
Continuous traction causes loosening 
of the hair from the follicles resulting in 
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inflammation i.e. folliculitis. If the traction 
continues, chronic inflammation ensues, 
which may lead to follicular atrophy with 
thinner, shorter hair. Initially the process 
is reversible, but follicular destruction, 
scarring and permanent hair loss may 
follow if traction persists. An associated 
posterior cervical lymphadenopathy is 
not uncommon.  
See CPD Questionnaire, page 34
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Press Release
ADVANCE trial:  Treating Hypertension vs. Lowering Blood 
Pressure: extending the benefi t?
Results from the largest ever study in 
type 2 diabetes, the ADVANCE study, 
will have important clinical implica-
tions for patients.  Diabetes mellitus is 
emerging as one of the greatest threats 
to the health of populations worldwide. 
Epidemiological data from the Inter-
national Diabetes Federation puts the 
current number of patients with diabetes 
at 7,1 million in Africa.  This number is 
estimated to rise to 15 million in 2025. 
The current prevalence of diabetes in 
South Africa varies from 5-30% depend-
ing on region, age and ethnicity, and it 
is well-known that these patients are at 
increased risk for cardiovascular com-
plications.  Most diabetic patients are 
also hypertensive, and the presence of 
hypertension further increases the car-
diovascular risk of diabetic patients.  
“People with diabetes have a two to four-
fold greater risk of experiencing a car-
diovascular event compared to non-dia-
betics.  However, despite this high risk, 
there is surprising little recent evidence 
from randomised clinical trials on the role 
of blood pressure lowering in the preven-
tion of diabetic vascular disease”, points 
out the ADVANCE study chairman John 
Chalmers from the George Institute.  
Previous trials in type 2 diabetic pa-
tients clearly demonstrated the benefit 
of lowering blood pressure in these pa-
tients.  However, the Blood Pressure 
target of 130/89 mmHg was never 
reached in these trials, and blood pres-
sure treatment seen as intensive was in 
fact not intensive by today’s standards. 
Therefore, the blood pressure lower-
ing arm of ADVANCE, with the use of 
Coversyl Plus® (perindopril 4mg and 
indapamide 1,25mg), aimed to begin 
lowering BP where previous trials have 
ended by including type 2 diabetic 
patients whatever their Blood Pressure 
level (average starting blood pressure 
145/81). These patients were included 
in order to demonstrate the benefit of 
blood pressure lowering, as opposed 
to only treating hypertension.  Coversyl 
Plus® was chosen specifically for AD-
VANCE, since perindopril has demon-
strated 24 hour blood pressure control, 
and both perindopril and indapamide 
are glucose and lipid neutral.  Added to 
this is the evidence that perindopril has 
proven benefits beyond blood pressure 
lowering.  
In ADVANCE, Coversyl Plus® was 
added to all existing therapy includ-
ing antihypertensives, lipid-lowering 
therapy and antiplatelet therapy.
For the physician, ADVANCE will 
show whether additional blood pres-
sure lowering with Coversyl Plus®, will 
reduce mortality and the risk of the 
type 2 diabetic developing macro - and 
microvascular complications. These 
results should ensure that blood pres-
sure lowering in this patient group, with 
an appropriately selected combination 
of agents, gets the attention that it de-
serves.
FOR MORE INFORMATION AND RE-
SULTS VISIT:  www.advance-trial.com
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